Form 4: Kezar Life Sciences Director Courtney's Stock Option Changes

Courtney reports changes in beneficial ownership of Kezar Life Sciences stock options following a merger.

Summary

• Courtney, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026.
• These transactions occurred in connection with a merger agreement, where certain stock options were cancelled.
• Options with an exercise price of $6.955 or higher were cancelled without consideration.
• Options with an exercise price below $6.955 were converted into a cash payment and a contingent value right (CVR).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the mechanics of stock option treatment following a merger, with no new financial performance data or strategic outlook.

Positives

• In-the-money stock options were converted into cash and CVRs, providing value to option holders.
• The merger was completed, indicating a significant corporate event for Kezar Life Sciences.

Negatives

• Out-of-the-money stock options were automatically cancelled and ceased to exist without any consideration.
• The specific cash amounts and CVR values are not detailed in this filing.

Risks

• The cancellation of out-of-the-money options represents a loss of potential future gains for some option holders.
• The value of the contingent value rights (CVRs) is uncertain and dependent on future events.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions related to a merger.

Management Comments

• Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer.
• Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.

Industry Context

StockSavvy.ai notes that the cancellation of out-of-the-money options and conversion of in-the-money options into cash and CVRs is a common practice in mergers and acquisitions within the biotechnology and pharmaceutical sectors, aiming to provide value to existing option holders while streamlining the capital structure of the combined entity.

Stakeholder Impact

• Shareholders: The merger likely results in a change of control and potential delisting of Kezar Life Sciences stock.
• Option Holders: Those with 'in-the-money' options receive cash and CVRs; those with 'out-of-the-money' options lose their holdings without compensation.
• Employees: Employees holding stock options will be directly impacted by the conversion terms.
• Management: Directors and officers, like Courtney, are subject to these option conversion terms.

Next Steps

• Shareholders and option holders will receive cash and/or CVRs as per the merger agreement.
• The company will continue to operate as a wholly owned subsidiary of Parent.

Key Dates

Keywords

Kezar Life Sciences, KZR, Form 4, Stock Options, Merger, Beneficial Ownership, Courtney Wallace, SEC Filing, Contingent Value Rights